GSK Lotronex To Be Reviewed By FDA Drug Safety Cmte. In April
FDA's Drug Safety & Risk Management Subcommittee will review the safety of GlaxoSmithKline's withdrawn irritable bowel syndrome agent Lotronex (alosetron) on April 23
FDA's Drug Safety & Risk Management Subcommittee will review the safety of GlaxoSmithKline's withdrawn irritable bowel syndrome agent Lotronex (alosetron) on April 23